{
    "clinical_study": {
        "@rank": "111088", 
        "arm_group": [
            {
                "arm_group_label": "BIIB031 1000 / 3000 PK Assessment", 
                "arm_group_type": "Experimental", 
                "description": "A single intravenous (IV) injection of BIIB031 50 IU/kg at a strength of 1000 IU/vial followed by a single IV injection of BIIB031 50 IU/kg at a strength of 3000 IU/vial."
            }, 
            {
                "arm_group_label": "BIIB031 3000 / 1000 PK Assessment", 
                "arm_group_type": "Experimental", 
                "description": "A single IV injection of BIIB031 50 IU/kg at a strength of 3000 IU/vial followed by a single IV injection of BIIB031 50 IU/kg at a strength of 1000 IU/vial."
            }, 
            {
                "arm_group_label": "BIIB031 Post PK Assessment", 
                "arm_group_type": "Experimental", 
                "description": "Following the PK assessment, patients will receive (in any combination of vial strength (250, 1000, or 3000 IU/vial)) either an episodic (on-demand) regimen with doses between 20 and 50 IU/kg based on the severity of the bleeding episode, or 1 of 2 prophylactic regimens: 50 IU/kg every 3 to 5 days or 65 IU/kg weekly. Particpants will be allowed to switch from 1 regimen to another if approved by the Investigator."
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study is to characterize the pharmacokinetics (PK) of BIIB031\n      administered from vial strengths of 1000 and 3000 IU in participants with severe hemophilia\n      A.  The secondary objective of the study is to evaluate the safety of BIIB031 beyond the PK\n      assessment for up to 6 months."
        }, 
        "brief_title": "Pharmacokinetics of BIIB031 at 2 Vial Strengths", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Severe Hemophilia A", 
        "condition_browse": {
            "mesh_term": "Hemophilia A"
        }, 
        "detailed_description": {
            "textblock": "This will be a randomized, open-label, crossover study during which each participant will\n      receive a single injection of BIIB031 from 2 different vial concentrations (pharmacokinetics\n      [PK] assessment). After the PK assessment, participants will be provided with BIIB031 for\n      either prophylactic or episodic (on-demand) treatment for up to 6 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Parental or guardian consent is required for subjects who are less than 18 years of\n             age or unable to give consent, or as applicable per local laws. Subjects who are less\n             than 18 years of age may provide assent in addition to the parental/guardian consent,\n             if appropriate.\n\n          -  Male, age \u226512 years at the time of informed consent, and weighing at least 40 kg.\n\n          -  Have severe hemophilia A\n\n          -  Previously treated subject, defined as having at least 150 documented prior exposure\n             days to any recombinant and/or plasma-derived FVIII and/or cryoprecipitate products\n             (other than any use of BIIB031 - study drug or commercial product) at Day 1. Fresh\n             frozen plasma treatment must not be considered in the count for documented exposure\n             days.\n\n          -  No history of a positive inhibitor test or clinical signs of decreased response to\n             FVIII administrations. Family history of inhibitors will not exclude subjects.\n\n          -  No measurable inhibitor activity using the Nijmegen-modified Bethesda assay at\n             Screening.\n\n          -  Platelet count \u2265100,000 platelets/\u03bcL at screening\n\n          -  CD4 lymphocytes >200 mm3 if known as HIV antibody positive at screening.\n\n          -  Viral load of <400 copies/mL if known HIV antibody positive at screening\n\n        Key Exclusion Criteria:\n\n          -  Subject is at high risk of bleeding during the 5-day period between the first and\n             second injections for PK analyses, as per Investigator discretion.\n\n          -  Previous treatment with BIIB031 as study drug or commercial product.\n\n          -  Other coagulation disorder(s) in addition to hemophilia A.\n\n          -  History of hypersensitivity or anaphylaxis associated with any FVIII or IV\n             immunoglobulin administration.\n\n          -  Currently taking (or likely to require during the study) acetylsalicylic acid (ASA),\n             except for low-dose ASA as prophylaxis (other nonsteroidal anti-inflammatory drugs\n             are permitted).\n\n          -  Concurrent systemic treatment with immunosuppressive drugs within 12 weeks prior to\n             Day 1. Exceptions to this include: ribavirin for treatment of hepatitis C virus\n             (HCV), and/or systemic steroids (a total of 2 courses of pulse treatments lasting no\n             more than 7 days at a dose of \u22641 mg/kg within 12 weeks prior to Day 1) and/or inhaled\n             steroids.\n\n        NOTE: Other protocol-defined inclusion/exclusion Criteria May Apply"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "16", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02083965", 
            "org_study_id": "997HA307", 
            "secondary_id": "2013-003013-18"
        }, 
        "intervention": {
            "arm_group_label": [
                "BIIB031 Post PK Assessment", 
                "BIIB031 1000 / 3000 PK Assessment", 
                "BIIB031 3000 / 1000 PK Assessment"
            ], 
            "description": "Intravenous Injection from either the 250 IU/vial, 1000 IU/vial, and/or 3000 IU/vial.", 
            "intervention_name": "BIIB031 (rFVIIIFc)", 
            "intervention_type": "Biological", 
            "other_name": [
                "recombinant coagulation factor VIII Fc fusion protein", 
                "rFVIIIFc"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Factor VIII"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "March 7, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Brisbane", 
                        "country": "Australia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Western Australia", 
                        "country": "Australia"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Johannesburg", 
                        "country": "South Africa"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hampshire", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "South Africa", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetics of 2 Vial Strengths of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc; BIIB031) in Previously Treated Subjects With Severe Hemophilia A", 
        "overall_contact": {
            "email": "clinicaltrials@biogenidec.com", 
            "last_name": "Biogen-Idec Investigator"
        }, 
        "overall_official": {
            "affiliation": "Biogen Idec", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration", 
                "South Africa: Medicines Control Council"
            ]
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "area under the concentration-time curve from time zero to infinity (AUCinf) as measured by activated partial thromboplastin time (aPTT) clotting assay", 
                "safety_issue": "No", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each injection"
            }, 
            {
                "measure": "incremental recovery (IR, K value) as estimated from the FVIII activity data measured by aPTT clotting assay", 
                "safety_issue": "No", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each injection"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02083965"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Maximum activity (Cmax) as measured by the aPTT clotting assay", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each of 2 injections."
            }, 
            {
                "measure": "half-life (t\u00bd), as measured by the aPTT clotting assay", 
                "safety_issue": "Yes", 
                "time_frame": "Up to  96 hours (\u00b160 minutes) after each of 2 injections."
            }, 
            {
                "measure": "Clearance (CL) as measured by the aPTT clotting assay", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each of 2 injections."
            }, 
            {
                "measure": "volume of distribution at steady state (Vss), as measured by the aPTT clotting assay", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each of 2 injections."
            }, 
            {
                "measure": "mean residence time (MRT) as measured by the aPTT clotting assay", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each of 2 injections."
            }, 
            {
                "measure": "Development of inhibitor as measured by the Nijmegen-modified Bethesda assay", 
                "safety_issue": "Yes", 
                "time_frame": "Months 3 and 6 of Treatment Period and at the Final Study Visit"
            }, 
            {
                "measure": "Maximum activity (Cmax) as measured by two-stage chromogenic clotting assay", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each of 2 injections."
            }, 
            {
                "measure": "half-life (t\u00bd), as measured by two-stage chromogenic clotting assay", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each of 2 injections."
            }, 
            {
                "measure": "Clearance (CL) as measured by two-stage chromogenic clotting assay", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each of 2 injections."
            }, 
            {
                "measure": "volume of distribution at steady state (Vss), as measured by two-stage chromogenic clotting assay", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each of 2 injections."
            }, 
            {
                "measure": "mean residence time (MRT) as measured by the two-stage chromogenic clotting assay", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 96 hours (\u00b160 minutes) after each of 2 injections."
            }
        ], 
        "source": "Biogen Idec", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Biogen Idec", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}